Spoon Feed
Molnupiravir is an oral antiviral drug that has been shown to decrease risk of hospitalization or death at 29 days in patients with mild to moderate COVID-19 who are at risk for progression to severe disease
Spoon Feed
New research on droperidol shows that it is a safe and effective medication for a multitude of common ED presentations, despite an FDA black box warning for QTc prolongation in 2001.
Spoon Feed
J-Tip lidocaine infusion did not reduce first-attempt IV success and reduced pain compared to no local anesthetic in children.
Spoon Feed
Outpatient IV remdesivir was effective in reducing COVID-related hospitalization in high risk outpatients.
Spoon Feed
In patients with moderate renal dysfunction (eGFR 15-59 mL/min/m2), giving 10 units vs 5 units of IV insulin for hyperkalemia did not result in a statistically significant difference in rates of hypoglycemia. Administering 10 units was shown to lower serum K by ~0.3 mmol/L more than 5 units.
Spoon Feed
Apixaban and rivaroxaban are two of the most prescribed direct oral anticoagulants (DOACs), but there are limited head-to-head comparisons of the medications. This study finds apixaban is associated with lower rates of VTE recurrence, GI bleeds and ICH compared to rivaroxaban.
Spoon Feed
Given the negligible downsides of TXA and the known harms of packing, it’s worth a try in our patients with epistaxis.
Spoon Feed
TXA is a safe and effective topical treatment for epistaxis, with 3.5 times greater odds of bleeding cessation at first reassessment compared to placebo, lidocaine plus vasoconstrictors, or local anesthetics.
Spoon Feed
A composite outcome encompassing both clinical response and adverse effects of antibiotics was superior in children who received 5 vs 10 days of antibiotics for pediatric community acquired pneumonia.
Spoon Feed
IV magnesium (IV-Mg) was associated with worsening asthma score in children, greater odds of hospitalization, and no acceleration of exacerbation resolution in hospitalized patients.
